ArticleInternational journal of clinical and experimental pathology2019
Expression of miR-182 and Foxo3a in patients with bladder cancer correlate with prognosis.
Article in International journal of clinical and experimental pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 8 citations in OpenAlex.
- Chemotherapy-induced alterations in miRNA expression and their prognostic implications in ovarian cancer.Frontiers in oncology · 2025Article
- Epigenetic Biomarkers as a New Diagnostic Tool in Bladder Cancer-From Early Detection to Prognosis.Journal of clinical medicine · 2024Review
- A novel microRNA-182/Interleukin-8 regulatory axis controls osteolytic bone metastasis of lung cancer.Cell death & disease · 2023Article
- MiR-182 Is Upregulated in Prostate Cancer and Contributes to Tumor Progression by Targeting MITF.International journal of molecular sciences · 2023Article
- circRNA CRIM1 regulates the migration and invasion of bladder cancer by targeting miR182/Foxo3a axis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Article
- FOXO3a inhibits nephroblastoma cell proliferation, migration and invasion, and induces apoptosis through downregulating the Wnt/β‑catenin signaling pathway.Molecular medicine reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveFoxO3a is a specific tumor suppressor gene in the forkhead transcription factor O subfamily (FoxO). Studies show that its expression plays a role in bladder cancer. The abnormal expression of miR-182 in bladder cancer suggests that miR-182 may be an oncogene in bladder cancer. Bioinformatic analysis showed that there is a target complementary binding site between miR-182 and Foxo3a. In this study, the expression of miR-182 and Foxo3a in cancer tissues of patients with bladder cancer was detected. The expression of miR-182 and Foxo3a in bladder cancer tissues and their relationship with the prognosis of the patients were analyzed, and the role of miR-182 in regulating the expression of Foxo3a and the biologic process of cell proliferation and apoptosis in bladder cancer cells was explored.
methodsTumor tissues of patients with bladder cancer were collected and the normal bladder mucosa was used as a control. The expression of Foxo3a was detected by western blot. The expression of miR-182 and Foxo3a mRNA was detected by qRT-PCR. The relationship between miR-182, Foxo3a mRNA and the clinical features of patients was analyzed. The median expression of miR-182 and Foxo3a mRNA was bounded, and Log Rank test was used to compare the survival rate of low and high expression of miR-182 and Foxo3a mRNA. The double luciferase reporter gene assay was used to confirm a target regulatory effect between miR-182 and Foxo3a. In vitro, RT112 and T24 cells were divided into 2 groups: group miR-NC, and group miR-182 inhibitor. qRT-PCR and western blot were used to detect the expression of Foxo3a, flow cytometry was used to detect cell apoptosis, and EdU staining was used to detect cell proliferation.
resultsCompared with normal bladder tissue, the expression of miR-182 in bladder cancer tissue was significantly increased, and it was related to tumor size, TNM stage, and lymph node metastasis (P < 0.05). The expression of Foxo3a mRNA was significantly decreased, and was related to tumor size, TNM stage, histopathologic classification, and lymph node metastasis (P < 0.05). There was a significant negative correlation between the expression of miR-182 and Foxo3a mRNA in bladder cancer (r = -0.602, P < 0.05). The prognosis of patients with high expression of miR-182 was significantly worse than that of those with low miR-182 expression. The prognosis of patients with low expression of Foxo3a was significantly better than those with high Foxo3a. Double luciferase reporter gene experiments confirmed that there was a target regulatory relationship between miR-182 and Foxo3a. Transfection of miR-182 inhibitor significantly increased the expression of Foxo3a in RT112 and T24 cells, significantly reducing cell proliferation, and significantly increasing apoptosis.
conclusionThe expression of miR-182 was increased and the expression of Foxo3a was decreased in bladder cancer, which is related to prognosis. Downregulation of the expression of miR-182 can increase the expression of Foxo3a, inhibiting the proliferation of bladder cancer cells and inducing apoptosis.
Indexed as
Identifiers
31933819PMC6949789W3008697484What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.